Steamboat Capital's Parsa Kiai Discloses 8.6% Medifast Stake After $10.5M Accumulation
MED sits 27% above its 52-week low of $9.22.
Summary
Steamboat Capital and Parsa Kiai disclosed an 8.6% Medifast stake — 963,286 shares bought for about $10.5 million — after a steady run of open-market purchases, including 100,000 shares on November 19.
Key Events · Ownership and Investor Activity · MED
-
8.6% Stake Disclosed in 13D/A
In Amendment No. 2 to their Schedule 13D, Steamboat Capital Partners, LLC and Parsa Kiai report beneficial ownership of 963,286 Medifast shares, equal to 8.6% of the class.
-
Roughly $10.5M Accumulated
Clients of the investment adviser acquired the reported shares in open-market purchases at an aggregate price of approximately $10,463,681, excluding commissions.
-
100,000 Shares Bought November 19
The 60-day transaction table shows 100,000 shares purchased on 11/19/2026 at a weighted average of $12.0464 (range $11.855-$12.15), plus 10,436 shares on 11/18 at $12.1613 and 6,480 on 10/28 at $12.2417.
-
Buying Through a Restructuring
The accumulation follows Q3 2026 revenue of $72.0 million, down 19.4%, and a $17.5 million net loss that included a $15.4 million restructuring charge.
Analysis · MED · Manufacturing
A disclosed 8.6% block with a documented buying pattern puts a large, motivated shareholder on the register — and that is what Parsa Kiai and Steamboat Capital now report: beneficial ownership of 963,286 Medifast shares, or 8.6% of the class, accumulated at an aggregate cost of roughly $10.5 million. The 13D/A formalizes an activist-style position built through repeated open-market buying — 6,480 shares on October 28, 661 on November 6, 10,436 on November 18 and 100,000 on November 19 at a weighted average of $12.0464 — while the company works through a restructuring and a 19.4% revenue decline. Such a stake can pressure management on capital allocation and strategy. The filing itself reports no agreement, board seat or stated intent beyond open-market purchases.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MED was trading at $11.72 on NYSE in the Manufacturing sector, with a market capitalization of approximately $131.1M. The 52-week trading range was $9.22 to $13.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.